TO THE EDITOR
=============

Autoimmune hemolytic anemia (AIHA) is a rare, but clinically significant complication following hematopoietic stem cell transplantation (HSCT). It is characterized by hemolysis due to antibodies produced by the donor's immune system against donor red cell antigens. The 3-year cumulative incidence of AIHA is 4.44% in adults; however, 75% of patients develop AIHA during the first post-HSCT year \[[@ref1]\]. AIHA after allogeneic HSCT has been associated with a variety of conditions, including chronic graft-versus-host disease (GVHD) \[[@ref2]\], T-cell depletion \[[@ref3]\], and unrelated donor transplants \[[@ref4]\]. HSCT from unrelated donors and the development of chronic extensive GVHD were the only independent factors associated with AIHA \[[@ref1]\]; however, the incidence of and risk factors for AIHA, as well as its prognosis and response to treatment remain unclear.

A 56-year-old male was diagnosed with high-risk acute myelogenous leukemia in April 2008. He was administered 8 cycles of chemotherapy, including idarubicin, cytosine arabinoside (ara-C), and sorafenib, and achieved complete remission. He remained in remission for 17 months, and then relapsed. He was treated with ara-C, and clofarabine, and achieved complete remission for the second time. He received a haploidentical (70% matched) bone marrow transplant (BMT) from his son on 03 March 2010, following conditioning with fludarabine, melphalan, and thiotepa, at the MD Anderson Cancer Center. GVHD prophylaxis was tacrolimus 1 mg p.o. twice daily and mycophenolate mofetil 1000 mg p.o. daily.

Stem cell infusion was uneventful, except for mild hypotension. The patient had mild veno-occlusive disease of the liver that eventually resolved, and several (4-5) episodes of CMV viremia, but no evident GVHD throughout his course. His blood type was A--, but the donor (son) was A+. The patient underwent bone marrow biopsy 3 months after transplantation, which showed 1% blasts and no flow cytometric evidence of relapse. Post-transplant microsatellite polymorphism was compatible with successful engraftment. No chimerism was observed. On post-transplant day 208 he presented with septic/hypotensive shock, and was supported with broad-spectrum antibiotics and intravenous fluids. He did not require mechanical ventilation or vasopressor therapy; however, deep anemia was noted (Hb: 3.8 g dL^--1^) and most of the RBC units cross-matched for transfusion appeared to be incompatible. It was noted that the patient's blood group had converted to A+, suggesting full erythroid donor chimerism. AIHA was diag nosed, based on fulfillment of all of the following criteria: positive direct antiglobulin test (DAT), negative indirect antiglobulin test (IAT), clinical and laboratory evidence of hemolysis (Table 1), and exclusion of other causes of immune hemolytic anemia.

Methylprednisolone 1 mg kg--1 (60 mg d--1) IV was initiated. Plasmapheresis with fresh frozen plasma (FFP) was performed (median exchange volume: 3014 mL) for 4 days. After the 1^st^, 2^nd^, and 3^rd^ plasmapheresis, DAT was positive and IAT was negative ([Table 1](#t1){ref-type="table"}). The reactives for the DAT test were polyspesific for IgG and C3d. Unfortunately, the patient's Hb value fell to 3.2 g dL--1 at that time ([Table 1](#t1){ref-type="table"}). IV immunoglobulin (IVIg) 25 g d^--1^ was administered the same day as the 2nd and 3rd plasmapheresis (after apheresis). Methylprednisolone was tapered to 40 mg d--1 on the fifth treatment day. As a result, the patient received 17 units of RBC, plasmapheresis 4 times, and IVIg twice during the course of treatment. Two weeks later AIHA was in control without RBC transfusion and the patient was discharged with an Hb value of 8.5 g dL--1 ([Table 1](#t1){ref-type="table"}). Methylprednisolone was tapered off within a month. Written informed consent was obtained from the patient.

Sanz et al. reported that most patients receive steroids as a primary treatment for AIHA and that the majority of cases do not respond \[1\]. Based on the response in the presented patient, plasmapheresis in addition to IVIg and corticosteroid should be considered a viable alternative treatment option in patients with AIHA that develops during the post-transplant period.
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###### The patient's laboratory results upon admission, after each plasmapheresis, and upon discharge.

![](TJH-29-199-g1)
